Understanding how a specific protein affects immune response in pancreatic cancer
Characterizing the biochemistry and dynamics of the immune suppressive CXCL12 coat in pancreatic cancer
This study is looking at a protein called CXCL12 that helps pancreatic cancer grow by keeping the immune system from fighting it, and researchers want to see if blocking this protein can help boost the immune response and improve treatment for people with pancreatic cancer.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | State University New York Stony Brook NIH-funded |
| Lab location | 1 site (Stony Brook, United States) |
| Project ID | NIH-10861802 on NIH RePORTER |
What this research studies
This research investigates the role of the CXCL12 protein in pancreatic ductal adenocarcinoma (PDAC), a type of pancreatic cancer with a very low survival rate. The study focuses on how CXCL12 interacts with cancer cells and suppresses the immune response, preventing effective treatment. By blocking this interaction, researchers aim to enhance T cell activity against the cancer, potentially improving patient outcomes. The research will involve biochemical analysis to understand the formation and breakdown of the CXCL12-KRT19 complex, which is crucial for immune suppression.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with pancreatic ductal adenocarcinoma who are seeking innovative treatment options.
Not a fit: Patients with other types of cancer or those who do not have pancreatic cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapeutic strategies that enhance immune responses in pancreatic cancer patients.
How similar studies have performed: Previous research has shown promise in targeting immune suppression mechanisms in other cancers, suggesting potential for success in this novel approach.
Where this research is happening
Stony Brook, United States
- State University New York Stony Brook — Stony Brook, United States (Active)
Researchers
- Principal investigator: Moresco, Philip Andrew — State University New York Stony Brook
- Study coordinator: Moresco, Philip Andrew
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.